MBX Biosciences, Inc. — Investor Relations & Filings
Filings indexed
167
across all filing types
Latest filing
2026-05-11
Regulatory Filings
Country
US
United States of America
Listing
US
MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for endocrine and metabolic diseases. The company is pioneering a proprietary platform of investigational Precision Endocrine Peptides (PEPs)™. This technology is designed to create highly specific and potent peptide therapeutics that address the underlying mechanisms of disease. MBX's pipeline targets rare and underserved endocrine disorders, such as hypoparathyroidism, with the goal of developing transformative, best-in-class medicines that simplify disease management and improve patients' quality of life.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-05-11 | English | |
| 8-K - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-05-07 | English | |
| 10-Q - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-05-07 | English | |
| ARS - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-04-22 | English | |
| DEF 14A - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-04-22 | English | |
| 144 - MBX Biosciences, Inc. (0001776111) (Subject) | 2026-03-25 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44942749 | 8-K - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-05-11 | English | ||
| 43062141 | 8-K - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-05-07 | English | ||
| 42970866 | 10-Q - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-05-07 | English | ||
| 35240462 | ARS - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-04-22 | English | ||
| 35239127 | DEF 14A - MBX Biosciences, Inc. (0001776111) (Filer) | 2026-04-22 | English | ||
| 33042401 | 144 - MBX Biosciences, Inc. (0001776111) (Subject) | 2026-03-25 | English | ||
| 32898067 | 4 - MBX BIOSCIENCES, INC. (0001776111) (Filer) | 2026-02-27 | English | ||
| 32898068 | 8-K - MBX BIOSCIENCES, INC. (0001776111) (Filer) | 2026-02-27 | English | ||
| 31668606 | SCHEDULE 13D/A Filing | 2026-02-11 | English | ||
| 31668614 | SCHEDULE 13G/A Filing | 2026-02-10 | English | ||
| 31668598 | 8-K Filing | 2026-02-05 | English | ||
| 31668643 | 4 Filing | 2026-02-03 | English | ||
| 31668593 | 4 Filing | 2026-02-03 | English | ||
| 31668588 | 4 Filing | 2026-02-03 | English | ||
| 31668667 | 4 Filing | 2026-01-22 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
MBX Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32409/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32409 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32409 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32409 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32409}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MBX Biosciences, Inc. (id: 32409)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.